Market Overview

Millendo Therapeutics to Participate in Upcoming Investor Conferences


Therapeutics, Inc.
, a clinical-stage biopharmaceutical company
focused on developing novel treatments for orphan endocrine diseases,
today announced that Julia C. Owens, Ph.D., President and Chief
Executive Officer, will participate in the following August conferences:

  • 2018 Oppenheimer Newport Summit for Revolutionary Biotechnology on
    Monday, August 13, 2018 in Newport, RI, where the Company will host
    investor meetings
  • 2018 Wedbush PacGrow Healthcare Conference, where the Company will
    provide a corporate overview and pipeline update on Wednesday, August
    15, 2018 at 9:45 AM ET in New York, NY

About Millendo Therapeutics, Inc.
Millendo Therapeutics is
focused on developing novel treatments for orphan endocrine diseases.
The Company's objective is to build a leading endocrine company that
creates distinct and transformative treatments for a wide range of
diseases where there is a significant unmet medical need. The Company is
currently advancing livoletide for the treatment of Prader-Willi
syndrome and nevanimibe for the treatment of classic congenital adrenal
hyperplasia and endogenous Cushing's syndrome. For more information,
please visit

View Comments and Join the Discussion!